JOPIC

The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Index
Original Article
Investigation of nuclear medicine techniques in surgically treated lung carcinoid tumors
Aims: Our aim in this study is to examine PET CT imaging techniques in patients with lung carcinoid tumors and to find the most appropriate preoperative nuclear medicine technique that can be performed for diagnosis or staging of these tumors.
Methods: The data of 123 patients who were operated on for lung carcinoid tumors in our center between 2009 and 2021 were evaluated retrospectively. Out of 123 patients, 123 had preoperative FDG-18 PET, 17 patients had preoperative GA-68 PET and 11 patients had postoperative GA-68 PET. Of the 123 patients, 17 were underwent both PET techniques preoperatively.
Results: In our lung carcinoid tumor patients, SUVmax of GA-68 PET was found to be much higher than FDG-18 PET (mean SUVmax : 20 vs 4.4). In GA-68 PET, mean SUVmax of the primary mass was 26 in typical carcinoid tumors, while 5.6 in atypical carcinoid tumors. In FDG-18 PET, mean SUVmax of the primary mass was 3.8 in the typical carcinoid tumors, while 5.4 in atypical carcinoid tumors.
Conclusion: GA-68 PET and FDG-18 PET SUVmax values in lung carcinoid tumors vary according to the subtype of the tumor. GA-68 PET shows higher SUVmax in typical carcinoid tumors, making GA-68 PET superior to FDG-18 PET in typical carcinoids. Although GA-68 PET shows higher SUVmax than FDG-18 PET in atypical carcinoid tumors, this difference does not reach a statistically significant level.


1. Karapolat İ. FDG PET/CT ımaging for evaluation of treatment response in lung cancer. Nukleer Tıp Seminerleri. 2018;4(1):43.
2. Kitajima K, Doi H, Kanda T, et al. Present and future roles of FDG-PET/CT imaging in the management of lung cancer. <em>Japan J Radiol</em>. 2016;34(6):387-99.
3. Krenning EP, Valkema R, Kwekkeboom DJ, et al. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. <em>J Nucl Med</em>. 2005;46(1 suppl):76S-82S.
4. Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: a review. <em>Clin Imaging</em>. 2020;67:113-116.
5. Jiang Y, Hou G, Cheng W. The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: a systematic review and meta-analysis. <em>Medicine</em>. 2019;98(10):e14769.
6. Lococo F, Perotti G, Cardillo G, et al. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid. <em>Clin Nucl Med</em>. 2015;40(3):e183-e9.
7. Ramirez RA, Chauhan A, Gimenez J, Thomas KE, Kokodis I, Voros BA. Management of pulmonary neuroendocrine tumors. <em>Rev Endocr Metab Disord</em>. 2017;18(4):433-442.
8. Rosado de Christenson ML, Abbott GF, Kirejczyk WM, Galvin JR, Travis WD. From the archives of the AFIP: thoracic carcinoids: radiologic-pathologic correlation. <em>Radiographics.</em> 1999;19(3):707-736.
9. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. <em>Cancer</em>. 2008; 113(10):2655-2664.
10. Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. <em>Eur J Nucl Med Mol Imaging</em>. 2013;40(11):1770-1780.
11. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? <em>Eur J Nucl Med Mol Imaging</em>. 2007;34(7):982-993.
12. Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. <em>Cmaj</em>. 2017;189(10):E398-E404.
13. Filosso PL, Oliaro A, Ruffini E, et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. <em>J Thorac Oncol</em>. 2013; 8(10):1282-1288.
14. Gosain R, Mukherjee S, Yendamuri SS, Iyer R. Management of typical and atypical pulmonary carcinoids based on different established guidelines. <em>Cancers</em>. 2018;10(12):510.
15. Singh S, Poon R, Wong R, Metser U. 68Ga PET imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis. <em>J Nucl Med</em>. 2018;43(11):802-810.
16. &Ouml;berg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol</em>. 2012;23(Suppl 7):vii124-vii130.
17. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. <em>J Nucl Med</em>. 2009;50(12):1927-1932.
18. Abdulrezzak U, Kurt YK, Kula M, Tutus A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. <em>Nucl Med Commun</em>. 2016;37(8):874-881.
Volume 2, Issue 4, 2024
Page : 77-81
_Footer